Shire reported a solid set of numbers for Q4 and the full year 2017. Immunology drove most of the growth while neuroscience lent strong support. The guidance, understandably, was not taken positively by the market, with the company expecting the top-line to grow at mid single-digit and profits at a slower pace. While we will be tweaking our estimates to account for the softer-than-expected outlook for 2018, we do not alter our already-modest long-term estimates.
19 Feb 2018
Solid results eclipsed by subdued guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid results eclipsed by subdued guidance
Shires Income PLC GBP (SHRS:LON) | 228 0 0.0% | Mkt Cap: 94.3m
- Published:
19 Feb 2018 -
Author:
Kamla Singh -
Pages:
3
Shire reported a solid set of numbers for Q4 and the full year 2017. Immunology drove most of the growth while neuroscience lent strong support. The guidance, understandably, was not taken positively by the market, with the company expecting the top-line to grow at mid single-digit and profits at a slower pace. While we will be tweaking our estimates to account for the softer-than-expected outlook for 2018, we do not alter our already-modest long-term estimates.